All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Court Rules No Link Between MMR Vaccine and Autism

February 19, 2009
By Pharmaceutical Technology Editors
News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

After two years of hearings, more than 5000 pages of expert testimonies, and 939 medical articles, a special federal court ruled that there was little, if any, evidence to support the claim that substances in the measles, mumps, and rubella vaccine (including the use of thimerosal) had led to the autism of three children.

Washington, DC (Feb. 12)-After two years of hearings, more than 5000 pages of expert testimonies, and 939 medical articles, a special federal court ruled that there was little, if any, evidence to support the claim that substances in the measles, mumps, and rubella vaccine (including the use of thimerosal) had led to autism of three children. Three special masters presiding in the US Court of Federal Claims made the landmark decisions in cases against the US Secretary of Health and Human Services in which the families sought compensation through the government’s Vaccine Injury Compensation Program.

More than 5500 claims have been made regarding a possible link between the MMR vaccine, especially in cases where thimerisol was used, and autism. According to the Office of Special Masters, the autism proceedings involved designating three test cases to be considered for each of three theories of “general causation.” One of these theories was dropped, so that during the hearings, the test cases were investigated against the other two; namely, the theory that MMR vaccines and thimerosal-containing vaccines can combine to cause autism and the theory that thimerosal-containing vaccines can cause autism.

The National Vaccine Injury Compensation Program (VICP) is a federal no-fault program enacted in 1986 and mandates that vaccine-injury claims be considered first under VICP. The statute was intended to reduce lawsuits against physicians and manufacturers, while providing those claiming vaccine injuries a reduced burden of proof. Claimants under the VICP need not prove negligence, failure to warn, or other tort causes of action; they must only prove that a covered vaccine caused injury.

The uncertainty regarding the safety of MMR vaccines has led to an increasing number of parents chosing not to have their child vaccinated. Some medical experts claim these decisions were a major factor leading to an increasing occurrence of measles in children, to the point that the Center for Disease Control and Prevention reported that in 2008 measles had reached the highest levels in more than a decade.

Regarding the special court decision, Leonard Rappaport, MD, MS, chief of the Division of Developmental Medince at Children’s Hospital Boston, said, “Hopefully this decision will put an end to this sad chapter in the search for the cause and treatment of autism spectrum disorders.”

Recent Videos
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Behind the Headlines, Episode 18
Drug Digest: Patient Preference Drives Solid Dosage Trends
Related Content

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS) | Image Credit: © Tada Images - stock.adobe.com

FDA Publishes More Than 200 Complete Response Letters

Christopher Cole
July 11th 2025
Article

FDA says the move boosts regulatory transparency, offering insights into common approval barriers in drug applications and reducing guesswork.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


Brain Injury, Blood in Injured Brains (stroke, brain hemorrhage, intracerebral hemorrhage, subarachnoid hemorrhage, arteriovenous malformation, brain aneurysm rupture, traumatic brain injury) | Image Credit: © Arugula Pica - stock.adobe.com

Generative AI-Driven Collaboration to Research Treatments for Brain Hemorrhage Complications

Patrick Lavery
July 9th 2025
Article

Delayed cerebral ischemia is a leading complication in the severe form of stroke known as subarachnoid hemorrhage and can result in long-term neurological damage, disability, or death.


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


Bone structure 3d illustration, normal and with osteoporosis | Image Credit: © adimas - stock.adobe.com

Theramex Treatment for Osteoporosis in Postmenopausal Women Accepted by Scottish Medicines Consortium

Patrick Lavery
July 7th 2025
Article

The company estimated that more than 1000 women in Scotland at very high risk of fracture would be eligible for treatment.


low angle view of marble dome of United States Capitol building in Washington DC with blue sky and visible architecture features | Image Credit: © Philip - stock.adobe.com

9 Implications of Trump’s Tax-Cut and Spending Bill for the Bio/Pharmaceutical Industry

Christopher Cole
July 7th 2025
Article

Trump’s tax bill could reshape drug R&D, manufacturing, Medicaid access, clinical trials, and biotech funding, impacting strategy across the bio/pharmaceutical industry.

Related Content

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS) | Image Credit: © Tada Images - stock.adobe.com

FDA Publishes More Than 200 Complete Response Letters

Christopher Cole
July 11th 2025
Article

FDA says the move boosts regulatory transparency, offering insights into common approval barriers in drug applications and reducing guesswork.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


Brain Injury, Blood in Injured Brains (stroke, brain hemorrhage, intracerebral hemorrhage, subarachnoid hemorrhage, arteriovenous malformation, brain aneurysm rupture, traumatic brain injury) | Image Credit: © Arugula Pica - stock.adobe.com

Generative AI-Driven Collaboration to Research Treatments for Brain Hemorrhage Complications

Patrick Lavery
July 9th 2025
Article

Delayed cerebral ischemia is a leading complication in the severe form of stroke known as subarachnoid hemorrhage and can result in long-term neurological damage, disability, or death.


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


Bone structure 3d illustration, normal and with osteoporosis | Image Credit: © adimas - stock.adobe.com

Theramex Treatment for Osteoporosis in Postmenopausal Women Accepted by Scottish Medicines Consortium

Patrick Lavery
July 7th 2025
Article

The company estimated that more than 1000 women in Scotland at very high risk of fracture would be eligible for treatment.


low angle view of marble dome of United States Capitol building in Washington DC with blue sky and visible architecture features | Image Credit: © Philip - stock.adobe.com

9 Implications of Trump’s Tax-Cut and Spending Bill for the Bio/Pharmaceutical Industry

Christopher Cole
July 7th 2025
Article

Trump’s tax bill could reshape drug R&D, manufacturing, Medicaid access, clinical trials, and biotech funding, impacting strategy across the bio/pharmaceutical industry.

About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.